SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001140361-19-007688
Filing Date
2019-04-26
Accepted
2019-04-26 15:46:26
Documents
5
Period of Report
2019-06-19
Effectiveness Date
2019-04-26

Document Format Files

Seq Description Document Type Size
1 DEF 14A nc10001312x1_def14a.htm DEF 14A 1381216
2 logo_cytomx.jpg GRAPHIC 84433
3 nc10001312x1_image01.jpg GRAPHIC 602608
4 nc10001312x1_proxycard1.jpg GRAPHIC 1439730
5 nc10001312x1_proxycard2.jpg GRAPHIC 1236172
  Complete submission text file 0001140361-19-007688.txt   5735891
Mailing Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080
Business Address 151 OYSTER POINT BLVD. SUITE 400 SOUTH SAN FRANCISCO CA 94080 650.515.3185
CytomX Therapeutics, Inc. (Filer) CIK: 0001501989 (see all company filings)

IRS No.: 273521219 | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37587 | Film No.: 19771563
SIC: 2834 Pharmaceutical Preparations